Please login to the form below

Trophos

This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Roche buys rare disease firm Trophos in €470m deal

Roche buys rare disease firm Trophos in 470m deal. Will take control of olesoxime for spinal muscular atrophy. ... Roche is paying 120m upfront for Marseilles-based Trophos, with another 350m promised in the form of milestone payments.
Christine Placet appointed CEO of Trophos

Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron. ... Prior to joining Trophos in 2004, Placet served as chief financial officer in several companies across various industries.
Actelion net revenue up 18 per cent for Q2

Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral
Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Deal Watch table for January 2015

Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.
Pharma deals during January 2015

A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Add my company

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...